In brief
- A study analyzing the medical records of over 300,000 U.S. veterans calculates how many people with PTSD might not even be eligible for MDMA-assisted therapy.
- Between 2018 and 2023, 15.3% to 17.3% of veterans had a potential contraindication, while more than half had a risk factor requiring monitoring rather than outright exclusion.
- Nearly nine out of ten were already taking medication that could interact with MDMA, though the authors believe most could still access therapy with proper clinical oversight.
As MDMA-assisted therapy for post-traumatic stress disorder (PTSD) continues its slow regulatory journey in the United States, a team from the Veterans Affairs (VA) health system in Portland has asked a different question. It is not whether MDMA works—that has already been studied extensively—but rather how many people with PTSD could actually be offered the treatment in practice once their full medical history is considered.
Who is excluded and who just needs monitoring
The study, published in the Journal of Psychoactive Drugs, cross-referenced clinical records from the VA health system between 2018 and 2023, requiring at least two PTSD diagnoses per calendar year. The annual sample size ranged from 303,451 to 326,315 people. The authors distinguish between two levels of concern. Potential contraindications, based on exclusion criteria from MDMA clinical trials, affected between 15.3% and 17.3% of veterans with active PTSD each year. Conditional risk factors, which require prior testing or adjustments without closing the door to treatment, affected 55.2% to 58.2%. Neither figure shifted significantly over the six-year period.
The most significant factor: existing medication
The most practical finding lies elsewhere. Each year, between 85.7% and 87.5% of these veterans were prescribed at least one medication with the potential to interact with MDMA. This is the figure that most complicates a real-world rollout of the therapy, as it does not depend on the PTSD diagnosis itself, but rather on the routine medication of a population that often manages multiple treatments simultaneously.
What this implies
This is a study of administrative records, not a clinical trial: it does not measure whether the therapy works, but rather how many people would encounter exclusion criteria before even attempting it. That is its value, as the debate over MDMA often remains focused on phase 3 trial efficacy and rarely addresses this more concrete question. The authors themselves insist that most of these risk factors are manageable through medication adjustments or medical monitoring, rather than being definitive vetoes. PTSD and MDMA are not inherently incompatible, but any access system that is eventually approved will have to contend with a population significantly more complex than those in clinical trials, where individuals taking other medications are typically screened out. For those already using MDMA on their own, whether within or outside of formal therapy, that same list of interactions—summarized in our harm reduction guides on MDMA and other entheogens—remains useful, regardless of whether the FDA approves anything this year.
Source
- Hwang CS, Cameron DC, O’Neill AC, Morasco BJ, Dobscha SK, Korthuis PT, Stauffer CS. Prevalence of Potential Contraindications and Risk Factors Relevant to MDMA-Assisted Therapy Among U.S. Veterans with Posttraumatic Stress Disorder. Journal of Psychoactive Drugs, August 5, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
